Clinical/Translational Cancer Immunotherapy

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003831; DOI: 10.1136/jitc-2021-003831
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e004025; DOI: 10.1136/jitc-2021-004025
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang, Xiangbin Xing, Sai-Ching Jim Yeung, Siyu Wang, Wenfang Chen, Yong Bao, Fang Wang, Shiting Feng, Fang Peng, Xiaoyan Wang, Shuling Chen, Minghui He, Ning Zhang, Honglei Wang, Bo Zeng, Zhenguo Liu, Biniam Kidane, Christopher W Seder, Kazuo Koyanagi, Yaron Shargall, Honghe Luo, Sui Peng, Chao Cheng

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003497; DOI: 10.1136/jitc-2021-003497
Exosomes derived from γδ-T cells synergize with radiotherapy and preserve antitumor activities against nasopharyngeal carcinoma in immunosuppressive microenvironment
Xiwei Wang, Yanmei Zhang, Xiaofeng Mu, Chloe Ran Tu, Yuet Chung, Sai Wah Tsao, Godfrey Chi-Fung Chan, Wing-Hang Leung, Yu-lung Lau, Yinping Liu, Wenwei Tu

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003832; DOI: 10.1136/jitc-2021-003832
Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
Shinya Abe, Hiroshi Nagata, Erika J Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, Tao Wang, Chaitanya R Acharya, Pankaj Agarwal, Joshua Snyder, William Gwin, Michael A Morse, Pei Zhong, Herbert Kim Lyerly, Takuya Osada

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003717; DOI: 10.1136/jitc-2021-003717
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Liye Zhou, Zexian Zeng, Ann Marie Egloff, Fan Zhang, Fei Guo, Katie M Campbell, Peter Du, Jingxin Fu, Paul Zolkind, Xiaojing Ma, Zhe Zhang, Yi Zhang, Xiaoqing Wang, Shengqing Gu, Rachel Riley, Yasutaka Nakahori, Joshua Keegan, Robert Haddad, Jonathan D Schoenfeld, Obi Griffith, Robert T Manguso, James A Lederer, X Shirley Liu, Ravindra Uppaluri

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e004034; DOI: 10.1136/jitc-2021-004034
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Ying Jing, Xue Chen, Kunyan Li, Yaoming Liu, Zhao Zhang, Yiqing Chen, Yuan Liu, Yushu Wang, Steven H Lin, Lixia Diao, Jing Wang, Yanyan Lou, Douglas B Johnson, Xiang Chen, Hong Liu, Leng Han

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003779; DOI: 10.1136/jitc-2021-003779
Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer
Shingo Maeda, Tomoki Motegi, Aki Iio, Kenjiro Kaji, Yuko Goto-Koshino, Shotaro Eto, Namiko Ikeda, Takayuki Nakagawa, Ryohei Nishimura, Tomohiro Yonezawa, Yasuyuki Momoi

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (2) e003731; DOI: 10.1136/jitc-2021-003731
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
Rosemina Merchant, Carole Galligan, Manjunatha Ankathatti Munegowda, L Bruce Pearce, Peter Lloyd, Paul Smith, Fahar Merchant, Minh D To

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003155; DOI: 10.1136/jitc-2021-003155
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003697; DOI: 10.1136/jitc-2021-003697

Main menu

Clinical/Translational Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical/Translational Cancer Immunotherapy

Pages